» Articles » PMID: 33495933

The Protective Effect of PK-11195 on Cognitive Impairment in Rats Survived of Polymicrobial Sepsis

Overview
Journal Mol Neurobiol
Date 2021 Jan 26
PMID 33495933
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Sepsis is an organ dysfunction caused by a host's unregulated response to infection, causing long-term brain dysfunction with microglial activation, the release of inflammatory components, and mitochondrial changes. Neuroinflammation can increase the expression of the 18-kD translocator protein (TSPO) in the mitochondria, leading to the activation of the microglia and the release of inflammatory components. The antagonist PK-11195 can modulate TSPO and reduce microglial activation and cognitive damage presented in an animal model of sepsis. The aim of this was to evaluate the effects of PK-11195 on long-term brain inflammation and cognitive impairment in an animal model of sepsis. Wistar rats, 60 days old, were submitted to cecal ligation and puncture (CLP) surgery, divided into groups control/saline, control/PK-11195, sepsis/saline, and sepsis/PK-11195. Immediately after surgery, the antagonist PK-11195 was administered at a dose of 3 mg/kg. Ten days after CLP surgery, the animals were submitted to behavioral tests and determination of brain inflammatory parameters. The sepsis/saline group presented cognitive damage. However, there was damage prevention in animals that received PK-11195. Besides, the sepsis increased the levels of cytokines and M1 microglia markers and caused oxidative damage. However, PK-11195 had the potential to decrease inflammation. These events show that the modulation of neuroinflammation during sepsis by PK-11195, possibly related to changes in TSPO, improves mitochondrial function in the animals' brains. In conclusion, the antagonist PK-11195 attenuated brain inflammation and prevented cognitive impairment in animals subjected to sepsis.

Citing Articles

Identification of iron metabolism-related genes as diagnostic signatures in sepsis by blood transcriptomic analysis.

Li H, Wang X, Yang Q, Cheng L, Zeng H Open Life Sci. 2023; 18(1):20220549.

PMID: 36820206 PMC: 9938542. DOI: 10.1515/biol-2022-0549.


Mitochondrial protective effects caused by the administration of mefenamic acid in sepsis.

Dominguini D, Michels M, Wessler L, Streck E, Barichello T, Dal-Pizzol F J Neuroinflammation. 2022; 19(1):268.

PMID: 36333747 PMC: 9636698. DOI: 10.1186/s12974-022-02616-6.


A crosstalk between gut and brain in sepsis-induced cognitive decline.

Giridharan V, Generoso J, Lence L, Candiotto G, Streck E, Petronilho F J Neuroinflammation. 2022; 19(1):114.

PMID: 35606817 PMC: 9125851. DOI: 10.1186/s12974-022-02472-4.

References
1.
Singer M, Deutschman C, Seymour C, Shankar-Hari M, Annane D, Bauer M . The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):801-10. PMC: 4968574. DOI: 10.1001/jama.2016.0287. View

2.
Yealy D, Huang D, Delaney A, Knight M, Randolph A, Daniels R . Recognizing and managing sepsis: what needs to be done?. BMC Med. 2015; 13:98. PMC: 4410741. DOI: 10.1186/s12916-015-0335-2. View

3.
Barichello T, Sayana P, Giridharan V, Arumanayagam A, Narendran B, Giustina A . Long-Term Cognitive Outcomes After Sepsis: a Translational Systematic Review. Mol Neurobiol. 2018; 56(1):186-251. DOI: 10.1007/s12035-018-1048-2. View

4.
Gordon S, Jackson J, Wesley Ely E, Burger C, Hopkins R . Clinical identification of cognitive impairment in ICU survivors: insights for intensivists. Intensive Care Med. 2004; 30(11):1997-2008. PMC: 7094980. DOI: 10.1007/s00134-004-2418-y. View

5.
Bozza F, dAvila J, Ritter C, Sonneville R, Sharshar T, Dal-Pizzol F . Bioenergetics, mitochondrial dysfunction, and oxidative stress in the pathophysiology of septic encephalopathy. Shock. 2013; 39 Suppl 1:10-6. DOI: 10.1097/SHK.0b013e31828fade1. View